{"ticker": {"uuid": "94f6d8a8-5841-4948-951d-f63d0f95de95", "symbol": "HRMY", "name": "Harmony Biosciences Holdings", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Harmony Biosciences Stock - Analyst consensus and technical backdrop", "summary": "Harmony Biosciences (HRMY) currently holds a \"Hold\" consensus from Wall Street analysts, trading in a defined range on Nasdaq. The stock closed at $33.28 on June 18, 2026, with analysts showing a cautious balance between buy, hold, and sell ratings. The company's primary revenue ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harmony-biosciences-stock-analyst-consensus-and-technical-backdrop/69592645", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:39:21", "published_display": "20 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Harmony Biosciences Holdings Inc (HRMY), noting its current valuation score of 8.08 and its ranking in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 13.36, which is significantly below its recent high ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:37", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Harmony Biosciences Holdings Inc's (HRMY) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also presents institutional shareholding data over several quarters, incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:20", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc", "summary": "The article provides a revenue breakdown for Harmony Biosciences Holdings Inc (HRMY), including market capitalization, P/E ratio, and stock performance. It notes that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:19", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones", "summary": "This article from Stock Traders Daily provides a detailed analysis of Harmony Biosciences Holdings Inc. (HRMY) using AI models to identify trading strategies across different risk profiles and holding periods. It highlights a strong near and mid-term sentiment, a significant risk", "url": "https://news.stocktradersdaily.com/news_release/39/Precision_Trading_with_Harmony_Biosciences_Holdings_Inc._HRMY_Risk_Zones_061526090803_1781572083.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T21:08:00", "published_display": "15 Jun 2026 21:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) Stock After New Pitolisant Data Reveals A 27.1% Undervaluation Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T03:33:29+00:00", "published_display": "14 Jun 2026 03:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance", "summary": "Harmony Biosciences (HRMY) is gaining attention after announcing new Pitolisant data presentations and reaffirming its guidance, leading to a 16.75% share price return in the last 30 days. Despite this short-term momentum, the stock has a modest 5.61% one-year return and a 10.2% ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harmony-biosciences-hrmy-stock-valuation-141344285.html", "source_name": "Market source", "published_at": "2026-06-12T14:09:17", "published_display": "12 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Using Pitolisant Data To Reframe Its Broader Neurology Pipeline Potential?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNbFlHbFFzUUtvTkppWXk5LTJOVkt4andzcGh4M0dZZXZIMWt1VVFnakYxQ0JtSG1CeHZfbkRrU0hUWFRvaF8yQXBDYmNGX2twUUxYM0c0T1lHYTJQN08zbEVLLUd0YXdTLVZieUJOZi1wbl9DTGMyWVQ0QVNWcjlVN0Q4UDZTUzFQbEVHZnR6RV9yN1JQR0hhTVhhNXk5aWdCRjAtMHY3VkJkRDVEWVl1eFhrUU9XaHV5SEtjdl9VWW41MkVITXBYNGR3XzdMQ1BuajRZdVJrMDctOUxfSF93ZG9Vc0VjZVVjVGF4T1VZMS1UcUo50gH6AUFVX3lxTE9IRTdOT0o4UzhBM0gyaVZlWVgyVEwwd2hPak9vNU1Qc3RTc0Vxc0d3TkxWVFNNa21yd2RmNjlxVFQ5QnkwaVpJVFNvOFFvMjQtUEJTVkR3ejZGWGNmalNVeGFGTFgyTXYyQ1dGMkxlOWwwNU9tMkRjOTZLaV9lSEU3MlFfaHhPdm1GOGpuZmFSZWFNMEFvY2JfZnJzU2J1bTZoLTJuTmpRYTI3TUtmSkJ6cnZoNllGQVJGMjkySjhmTG1GUldFTHdfQkV1cEV1bEFhckdEUEdSYWpPejBuZ0pMNHowTWlFNFRURjVNU3MzRktLVDUzMVJaRWc?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T11:37:37+00:00", "published_display": "12 Jun 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Six narcolepsy and hypersomnia studies from Harmony at SLEEP 2026", "summary": "Harmony Biosciences (Nasdaq: HRMY) announced that six of its abstracts focusing on narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at the SLEEP 2026 annual meeting. These presentations include analyses of Pitolisant's effects on sleep patterns, re", "url": "https://www.stocktitan.net/news/HRMY/harmony-biosciences-announces-poster-presentations-at-2026-sleep-6akmi8lj0c1u.html", "source_name": "Stock Titan", "published_at": "2026-06-12T06:09:53", "published_display": "12 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) is presented as a compelling investment opportunity due to its undervaluation, strong performance of its flagship drug WAKIX, and promising growth pipeline. The company exhibits robust financial health with high gross margins and self-fun", "url": "https://www.insidermonkey.com/blog/is-harmony-biosciences-holdings-inc-hrmy-a-good-stock-to-buy-now-1754557/", "source_name": "Insider Monkey", "published_at": "2026-06-11T14:40:04", "published_display": "11 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY (NASDAQ) affiliate: option exercise 27,960 shares; Kapadia sells 54,646", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) affiliate reported a Form 144 filing detailing the exercise of options for 27,960 shares and the sale of 54,646 common shares by Sandip Kapadia across several transactions in May and June 2026. The filing provides specific dates, share co", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-7518335f703c.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:09:32", "published_display": "09 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY affiliate files Rule 144 sale notice (NASDAQ: HRMY) for option exercises", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) submitted a Rule 144 notice for proposed common stock sales related to option exercises on June 5, 2026. The filing indicates recent dispositions of 7,064 shares for $233,232.09 on June 4, 2026, and 45,481 shares for $1,433,056.28 on May ", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-0095ef720d4c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:45", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandip Kapadia files Form 144 proposing sale of 45,481 HRMY shares (HRMY)", "summary": "Sandip Kapadia has filed a Form 144 indicating a proposed sale of 45,481 shares of Harmony Biosciences Holdings, Inc. (HRMY). The filing details a completed sale on May 8, 2026, for an aggregate amount of $1,433,056.28, and a planned transaction tied to an option exercise under a", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-e404d5d77b4a.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:58", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to HRMY Trends in Macro Strategies", "summary": "This article from Stock Traders Daily provides a technical analysis of Harmony Biosciences Holdings Inc. (NASDAQ: HRMY), highlighting a strong near and mid-term sentiment that could extend to the long term. It identifies a mid-channel oscillation pattern and offers three distinct", "url": "https://news.stocktradersdaily.com/news_release/43/Technical_Reactions_to_HRMY_Trends_in_Macro_Strategies_060426073802_1780616282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-04T19:38:00", "published_display": "04 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. -- Barrons.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOTVIwZ213blRmcmxSc0paMmRqRmdmMUNINWVocUR6OEZZRTJZdWxnc09nbXF3U0wwdlI1U0ZVam9jcGoxQThsdFQzSlVGdnFHS2dkWG9JeUh6TldiLTNvcWdqSHFsU0pBQUZKSk0xeGxJQlM0QVRoa0U0YTNKcG5jNERXT0dSOFFrdlR3c2hlSWk4clVaVTVEZXZ5aThWRGx3azhJcFcwMlJXN0thR2xHSGNn?oc=5", "source_name": "Moomoo", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSDFEbW9LWF94bG1YbHJCOGZFcFNPeVM0R25FVW1CempjdmJoQ1B3bnhPLTZ0andDRWJVaEYwMVMwbFZwUFVkbW9UZ3BxWnJob1NibzRTeXBGRFhubWphNmJua0w5Ni00SzlCWi12aHl1Q3Vqc0RZS09PQ05XZEZGMU9GSjc4WFVTUGota2pDeDAzSWc0RGFua0JibEI3WGR2cHNZNw?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences to Participate in Upcoming Investor Conferences", "summary": "Harmony Biosciences (Nasdaq: HRMY) announced its management team will attend two investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026. Webcasts of the fireside chats will", "url": "https://www.businesswire.com/news/home/20260527892644/en/Harmony-Biosciences-to-Participate-in-Upcoming-Investor-Conferences", "source_name": "Business Wire", "published_at": "2026-05-27T12:10:19", "published_display": "27 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Harmony Biosciences stock rating at buy", "summary": "H.C. Wainwright maintained a Buy rating and a $55.00 price target for Harmony Biosciences (NASDAQ:HRMY) despite the company missing first-quarter 2026 revenue and GAAP EPS consensus estimates. The miss was primarily due to high licensing expenses, but Harmony Biosciences remains ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-harmony-biosciences-stock-rating-at-buy-93CH-4706430", "source_name": "Investing.com", "published_at": "2026-05-22T21:09:50", "published_display": "22 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides a comprehensive collection of SEC filings for Harmony Biosciences Holdings, Inc. (HRMY), including 10-K, 10-Q, 8-K forms, and insider trading reports. Each filing is accompanied by an AI-generated summary, impact score, and sentiment analysis. Rec", "url": "https://www.stocktitan.net/sec-filings/HRMY/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-22T14:11:01", "published_display": "22 May 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)", "summary": "H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a price target of $55.00 for the company. The full article content is only available to premium subscribers.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/26538371.html", "source_name": "StreetInsider", "published_at": "2026-05-22T11:08:55", "published_display": "22 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities", "summary": "Harmony Biosciences reported its Q1 financial results and reaffirmed its 2026 net revenue guidance of over $1 billion. The company also reinforced its strategic priorities for 2026. This announcement indicates the company's confidence in its future financial performance and strat", "url": "https://www.quantisnow.com/insight/harmony-biosciences-reports-q1-financial-results-and-confirms-2026-net-6537465", "source_name": "Quantisnow", "published_at": "2026-05-21T07:41:54", "published_display": "21 May 2026 07:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Revenue Rises as WAKIX Franchise Expands", "summary": "Harmony Biosciences reported a 17% revenue increase for its narcolepsy drug WAKIX in the first quarter, reaching $215.4 million, and reaffirmed its full-year revenue guidance between $1 billion and $1.04 billion. The company is actively expanding its WAKIX franchise through paten", "url": "https://www.mychesco.com/a/news/regional/harmony-revenue-rises-as-wakix-franchise-expands/", "source_name": "MyChesCo", "published_at": "2026-05-20T23:10:44", "published_display": "20 May 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price", "summary": "Harmony Biosciences director Juan A. Sabater was granted 21,872 stock options with an exercise price of $30.76 per share, vesting on the earlier of May 14, 2027, or the next annual meeting, provided he continues service. These options expire on May 14, 2036. This transaction is a", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-de41ac975c9a.html", "source_name": "Stock Titan", "published_at": "2026-05-20T13:10:36", "published_display": "20 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A beaten-down biotech just lost a meaningful backer \u2014 should you care?", "summary": "Bridge City Capital, LLC, has fully divested its investment in Harmony Biosciences Holdings (NASDAQ:HRMY) during the first quarter of 2026, selling all 237,103 shares for an estimated $7.77 million. Harmony Biosciences, a healthcare company, focuses on developing treatments for r", "url": "https://www.sharewise.com/de/news_articles/A_beatendown_biotech_just_lost_a_meaningful_backer_should_you_care_TheMotleyFool_20260519_2353", "source_name": "www.sharewise.com", "published_at": "2026-05-20T02:09:07", "published_display": "20 May 2026 02:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director receives 21,872-share stock option grant", "summary": "Harmony Biosciences director Linda M. Szyper was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. This grant serves as compensation, not an open-market purchase, and vests fully on the earlier of May 14, 2027, or the next annual m", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-6195f3dfc2a1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T07:10:44", "published_display": "19 May 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3", "summary": "Harmony Biosciences Holdings, Inc. director Germano Geno J has filed an initial Form 3 with the SEC, which officially lists him as a reporting person for the company. This filing is a mandatory first insider ownership report for company officers, directors, and large shareholders", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-3-harmony-biosciences-holdings-inc-initial-statement-of-benefici-4dfd4b9adbc3.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:39:21", "published_display": "19 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director granted 21,231 stock options", "summary": "Harmony Biosciences Holdings, Inc. director Germano Geno J was granted 21,231 stock options as equity compensation. These options, with an exercise price of $30.76 per share and an expiration date of May 14, 2036, will vest in 36 equal monthly installments starting on June 14, 20", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-8306724de5f0.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:39:21", "published_display": "19 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences director granted 21,872 options | HRMY Insider Trading", "summary": "Harmony Biosciences director Philip Ron M was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. The options will vest in full by May 14, 2027, or the date of the next annual meeting, contingent on his continued service. This transa", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-6d7dbcc5b2f9.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:39:21", "published_display": "18 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)", "summary": "Harmony Biosciences (HRMY) reported a dip in net income for Q1 2026, though net product revenue grew by 17%. The company is focused on WAKIX, having received FDA approval for pediatric cataplexy and actively pursuing patent protection into 2030, despite near-term earnings pressur", "url": "https://www.sahmcapital.com/news/content/earnings-dip-revenue-growth-and-patent-moves-might-change-the-case-for-investing-in-harmony-biosciences-hrmy-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-16T06:09:43", "published_display": "16 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Harmony Biosciences Holdings, Inc. \u2013 NASDAQ:HRMY", "summary": "This article provides limited information regarding the number of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), indicating that data for specific periods and values can be accessed. It also notes various market data and reference data providers while listing ", "url": "https://www.tradingview.com/symbols/NASDAQ-HRMY/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-15T20:10:10", "published_display": "15 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Harmony Biosciences Shareholders Approve Governance Measures at Meeting", "summary": "Harmony Biosciences Holdings (HRMY) shareholders recently approved key governance measures at their 2026 Annual Meeting. They elected four Class III directors, ratified Deloitte & Touche LLP as the independent auditor, and endorsed executive compensation, indicating strong shareh", "url": "https://www.tipranks.com/news/company-announcements/harmony-biosciences-shareholders-approve-governance-measures-at-meeting", "source_name": "TipRanks", "published_at": "2026-05-14T23:40:02", "published_display": "14 May 2026 23:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNDF4OHlBWkxnODQ3TTF5eGZqNVBUSGFQalF4NjBtR25TSmJfYzhjN0NhbERMSWRkak9yTmp5eXVSZU5RSnEzSjdYMzZWTEF4d0NQYjVoM2Ftcm5aUXU2MEVBRGNqQU1hZl9pZ01RbG5FMmZPQkZLXy1LZjNkV1RhSjBneGlmTmhFWmYzNHBUU1BuTUNXUzdmbC14V0dtSUhQOFB0bW9qZHpQdw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Harmony Biosciences\u2019 Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPUUgxMzFqMFRlN2JDZ3RObTRJSmhld2xZRUhaNFpqN0tRd1VxeEpJMkVXMWxSaGNpd1M1ZF9qbDZQMGhlQUZpblBoenU3VXI1djZ0VVczNTZIZlFWVUFqMVMtMk81UDl2Ri1DT0JSM3JBZjh6X3VfemN2WjdrdjJyR3RLR2tqUnByS0V5LUZLZDZIVm1XSzNOaHlXLXBVd2w1Z0c5b253?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN2tHV0E0dk1wWUxpUHNLZU1uME9DeG9uYVQwQTQtaXZwTzUtWWlyRTFOZDFCcGsyM1VQR2ZYb1YtUXNqUDM3OWVzUkRsSkxDdnJYa3ZfX2tjczdyajd6M2VtYnR0M2VDS25EQldLZ1h6TnJkVDEySnBOSlBwVGN4Vm5RalZnclY2c05ySU4yTlBZYW5aSk9mYUM2OWQ1Z2t3RWhrTE1BYmh3VnM5LUE?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit Harmony Biosciences Holdings (HRMY) After Its Recent Share Price Rebound?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond (NASDAQ:HRMY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQc05OcnBGRDJCdVpLUnJCM1J1XzRJUnktanZpamd2OVA5S3UxdjZ3VUZWeU5LS215UEtVSkRiODZ1blcwOUdmOHRXNTJsQms3WUxlUGdwTjJTSkRONjJsSHVpZjZMS0tlWTBlRTFQRlplZjJmRmhHMTFZNno1blFsQUlyV3RMeWtaR3Y4TE1TU21sYkN0MW4yT0xSaFZ3ZzNWNm5nRmVLeFk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "HARMONY BIOSCIENCES ($HRMY) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOMktvLU1lQ01BQVExVnlCQmVZQjBYUGp0dG1wbWVzRDd1TmNzSFA2UkZ0UzVZQ2hNM01LUm1mU3NBMEVIRG5yLU9HdnVjZldLRVpISkIwWlZYdEFPblVHY3NKWGR2d2tFRFUxYnNOZTVVNm5DQVE2ZVlGTVk3LTFpTXVwMzhxZmtkYkxQaUZ6cVZMcDdHdkZF?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Gains Pediatric WAKIX Approval As Valuation Draws Attention", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOckpxNDNLWnpGZXpMYkFMNTZHUVdNQy1wMnJQd0p4bE5rZU1WM1d3UUpfWC03VGNJQ2dHOTNoX1p6Uk02cHMzN01mTUlfNVBtejdKRDQ0SlVRYjNodFgta2tsNS1yYmlQcWpKVm1TSXBPZ2RSMGVYUzJfb1N6THJsaTl1REwzSW85LUVoMjFiTGE1RUZGUnlhcDM0dGROTWpyUXEwZ3hmdHQyZUxjWE1IWmtaWGFmc2NDV2hnVFJWVVVJNjd5V0F1YXcwd1NRTExZZ1lNQkRPaHZFem1wTk0tWUF4NGlxbVE3RGdJZXo3dGxEM3NmOXpXWjhDNllOdTE1SGZlM0R6clBEaUxfa3RYMEdpcW5RWU9XYmZJanNVaWJhSHRLSXBVVUJvek4?oc=5", "source_name": "Business Wire", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPOEtsNnpwbnRDdGs4c0JmTzFOLXByTmtDMkJtNjl5NlMwLVhzTklDTnNYeDhrc1U5QUxIcTlZV3pvMmpTLU5QMzFoLWRXb1B4YjBtUFJQQ05ZX2pCdElyVkg5cW1HOGtCTVVPM3NnMWFoandjQzZwZjFEc29kR2UtNmUxbDFJd0NKWS1iYnRXaWozQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQaTZ3WlQ5VGtqVHJHOFgzYU93NG1aMV83WFRCakF4UUp0ZnktS1FGNHh3MUdleTBYcGxuem85dUhrSlc0U1NBTmM1Z0hDRlcya09XQ0c4Umd4OE5SbGpyZDZ6VXYxTkYyeHdhMU5HbGpvZ0FXMEhUa2ZjclJUOC14UXJCMTJmaDFVZjFB?oc=5", "source_name": "Market source", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVDJFeE1DS2JwR1l5b19ES3Z2SUlOVnk4cGV1VHhKR05qek04YTJUVHdad0VwemI0Z19FZno4Tl92Rk9yT1RaWmxNWElPV0JGSWJDU0N0dE9rY0RYbmFrTzd6dEd4SHhqWmtsSXRuQWNlNmpSdzRzZldhZzhMNHZPakhlbjRCZDRSbkhWSUQ2NTROR2I1YlFn?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Harmony Biosciences (HRMY) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNNjlfZWRuc2p0dmdJZzlsMU1GampfcE5jcUV2QTlDZ2FuYWZvNWNHb3hTcnFsOWlOWFNUMWZzNlQyempVVGh1MjVUZzJRZkwtX2xUVWgtWjVjOUtHNWlMa3QwWjRSby1QRTNTUzFIdHpMbFk4SzRuZHZ5R0dXUkxDRklZUG9CWjZmcHVnSEh3?oc=5", "source_name": "Market source", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Pricing Reflect Future Growth After Recent Mixed Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVFEyY3VKMmFOSmFGZHZpR0FrUDlUQnh1emJZbDZFeHJmbG1RSlJjcFE1VzFBa0RNVzZYWGRuQ29ZNDN5bE1WeUtlb3F2TGl1WmRvSTBIUzRrTVB5c0J5VmFWREF3S29nbWc0WE51cHVIYlAwc0w2TjRyaTNsMC02ZU1aQ3JQRXh5b0pUNnJVbw?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Harmony Biosciences Stock - Analyst consensus and technical backdrop", "summary": "Harmony Biosciences (HRMY) currently holds a \"Hold\" consensus from Wall Street analysts, trading in a defined range on Nasdaq. The stock closed at $33.28 on June 18, 2026, with analysts showing a cautious balance between buy, hold, and sell ratings. The company's primary revenue ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/harmony-biosciences-stock-analyst-consensus-and-technical-backdrop/69592645", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T18:39:21", "published_display": "20 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Harmony Biosciences Holdings Inc (HRMY), noting its current valuation score of 8.08 and its ranking in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 13.36, which is significantly below its recent high ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:37", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Harmony Biosciences Holdings Inc's (HRMY) shareholder structure, listing major shareholders and their proportions, as well as categorizing shareholder types. It also presents institutional shareholding data over several quarters, incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:20", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings Inc", "summary": "The article provides a revenue breakdown for Harmony Biosciences Holdings Inc (HRMY), including market capitalization, P/E ratio, and stock performance. It notes that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrmy/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:19", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones", "summary": "This article from Stock Traders Daily provides a detailed analysis of Harmony Biosciences Holdings Inc. (HRMY) using AI models to identify trading strategies across different risk profiles and holding periods. It highlights a strong near and mid-term sentiment, a significant risk", "url": "https://news.stocktradersdaily.com/news_release/39/Precision_Trading_with_Harmony_Biosciences_Holdings_Inc._HRMY_Risk_Zones_061526090803_1781572083.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T21:08:00", "published_display": "15 Jun 2026 21:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) Stock After New Pitolisant Data Reveals A 27.1% Undervaluation Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-14T03:33:29+00:00", "published_display": "14 Jun 2026 03:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance", "summary": "Harmony Biosciences (HRMY) is gaining attention after announcing new Pitolisant data presentations and reaffirming its guidance, leading to a 16.75% share price return in the last 30 days. Despite this short-term momentum, the stock has a modest 5.61% one-year return and a 10.2% ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/harmony-biosciences-hrmy-stock-valuation-141344285.html", "source_name": "Market source", "published_at": "2026-06-12T14:09:17", "published_display": "12 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Using Pitolisant Data To Reframe Its Broader Neurology Pipeline Potential?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T11:37:37+00:00", "published_display": "12 Jun 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Six narcolepsy and hypersomnia studies from Harmony at SLEEP 2026", "summary": "Harmony Biosciences (Nasdaq: HRMY) announced that six of its abstracts focusing on narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at the SLEEP 2026 annual meeting. These presentations include analyses of Pitolisant's effects on sleep patterns, re", "url": "https://www.stocktitan.net/news/HRMY/harmony-biosciences-announces-poster-presentations-at-2026-sleep-6akmi8lj0c1u.html", "source_name": "Stock Titan", "published_at": "2026-06-12T06:09:53", "published_display": "12 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) is presented as a compelling investment opportunity due to its undervaluation, strong performance of its flagship drug WAKIX, and promising growth pipeline. The company exhibits robust financial health with high gross margins and self-fun", "url": "https://www.insidermonkey.com/blog/is-harmony-biosciences-holdings-inc-hrmy-a-good-stock-to-buy-now-1754557/", "source_name": "Insider Monkey", "published_at": "2026-06-11T14:40:04", "published_display": "11 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY (NASDAQ) affiliate: option exercise 27,960 shares; Kapadia sells 54,646", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) affiliate reported a Form 144 filing detailing the exercise of options for 27,960 shares and the sale of 54,646 common shares by Sandip Kapadia across several transactions in May and June 2026. The filing provides specific dates, share co", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-7518335f703c.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:09:32", "published_display": "09 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY affiliate files Rule 144 sale notice (NASDAQ: HRMY) for option exercises", "summary": "Harmony Biosciences Holdings, Inc. (HRMY) submitted a Rule 144 notice for proposed common stock sales related to option exercises on June 5, 2026. The filing indicates recent dispositions of 7,064 shares for $233,232.09 on June 4, 2026, and 45,481 shares for $1,433,056.28 on May ", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-0095ef720d4c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:45", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sandip Kapadia files Form 144 proposing sale of 45,481 HRMY shares (HRMY)", "summary": "Sandip Kapadia has filed a Form 144 indicating a proposed sale of 45,481 shares of Harmony Biosciences Holdings, Inc. (HRMY). The filing details a completed sale on May 8, 2026, for an aggregate amount of $1,433,056.28, and a planned transaction tied to an option exercise under a", "url": "https://www.stocktitan.net/sec-filings/HRMY/144-harmony-biosciences-holdings-inc-sec-filing-e404d5d77b4a.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:08:58", "published_display": "04 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to HRMY Trends in Macro Strategies", "summary": "This article from Stock Traders Daily provides a technical analysis of Harmony Biosciences Holdings Inc. (NASDAQ: HRMY), highlighting a strong near and mid-term sentiment that could extend to the long term. It identifies a mid-channel oscillation pattern and offers three distinct", "url": "https://news.stocktradersdaily.com/news_release/43/Technical_Reactions_to_HRMY_Trends_in_Macro_Strategies_060426073802_1780616282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-04T19:38:00", "published_display": "04 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. -- Barrons.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOTVIwZ213blRmcmxSc0paMmRqRmdmMUNINWVocUR6OEZZRTJZdWxnc09nbXF3U0wwdlI1U0ZVam9jcGoxQThsdFQzSlVGdnFHS2dkWG9JeUh6TldiLTNvcWdqSHFsU0pBQUZKSk0xeGxJQlM0QVRoa0U0YTNKcG5jNERXT0dSOFFrdlR3c2hlSWk4clVaVTVEZXZ5aThWRGx3azhJcFcwMlJXN0thR2xHSGNn?oc=5", "source_name": "Moomoo", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNSDFEbW9LWF94bG1YbHJCOGZFcFNPeVM0R25FVW1CempjdmJoQ1B3bnhPLTZ0andDRWJVaEYwMVMwbFZwUFVkbW9UZ3BxWnJob1NibzRTeXBGRFhubWphNmJua0w5Ni00SzlCWi12aHl1Q3Vqc0RZS09PQ05XZEZGMU9GSjc4WFVTUGota2pDeDAzSWc0RGFua0JibEI3WGR2cHNZNw?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences to Participate in Upcoming Investor Conferences", "summary": "Harmony Biosciences (Nasdaq: HRMY) announced its management team will attend two investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026. Webcasts of the fireside chats will", "url": "https://www.businesswire.com/news/home/20260527892644/en/Harmony-Biosciences-to-Participate-in-Upcoming-Investor-Conferences", "source_name": "Business Wire", "published_at": "2026-05-27T12:10:19", "published_display": "27 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Harmony Biosciences stock rating at buy", "summary": "H.C. Wainwright maintained a Buy rating and a $55.00 price target for Harmony Biosciences (NASDAQ:HRMY) despite the company missing first-quarter 2026 revenue and GAAP EPS consensus estimates. The miss was primarily due to high licensing expenses, but Harmony Biosciences remains ", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-harmony-biosciences-stock-rating-at-buy-93CH-4706430", "source_name": "Investing.com", "published_at": "2026-05-22T21:09:50", "published_display": "22 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides a comprehensive collection of SEC filings for Harmony Biosciences Holdings, Inc. (HRMY), including 10-K, 10-Q, 8-K forms, and insider trading reports. Each filing is accompanied by an AI-generated summary, impact score, and sentiment analysis. Rec", "url": "https://www.stocktitan.net/sec-filings/HRMY/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-22T14:11:01", "published_display": "22 May 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)", "summary": "H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a price target of $55.00 for the company. The full article content is only available to premium subscribers.", "url": "https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/26538371.html", "source_name": "StreetInsider", "published_at": "2026-05-22T11:08:55", "published_display": "22 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities", "summary": "Harmony Biosciences reported its Q1 financial results and reaffirmed its 2026 net revenue guidance of over $1 billion. The company also reinforced its strategic priorities for 2026. This announcement indicates the company's confidence in its future financial performance and strat", "url": "https://www.quantisnow.com/insight/harmony-biosciences-reports-q1-financial-results-and-confirms-2026-net-6537465", "source_name": "Quantisnow", "published_at": "2026-05-21T07:41:54", "published_display": "21 May 2026 07:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Revenue Rises as WAKIX Franchise Expands", "summary": "Harmony Biosciences reported a 17% revenue increase for its narcolepsy drug WAKIX in the first quarter, reaching $215.4 million, and reaffirmed its full-year revenue guidance between $1 billion and $1.04 billion. The company is actively expanding its WAKIX franchise through paten", "url": "https://www.mychesco.com/a/news/regional/harmony-revenue-rises-as-wakix-franchise-expands/", "source_name": "MyChesCo", "published_at": "2026-05-20T23:10:44", "published_display": "20 May 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price", "summary": "Harmony Biosciences director Juan A. Sabater was granted 21,872 stock options with an exercise price of $30.76 per share, vesting on the earlier of May 14, 2027, or the next annual meeting, provided he continues service. These options expire on May 14, 2036. This transaction is a", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-de41ac975c9a.html", "source_name": "Stock Titan", "published_at": "2026-05-20T13:10:36", "published_display": "20 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A beaten-down biotech just lost a meaningful backer \u2014 should you care?", "summary": "Bridge City Capital, LLC, has fully divested its investment in Harmony Biosciences Holdings (NASDAQ:HRMY) during the first quarter of 2026, selling all 237,103 shares for an estimated $7.77 million. Harmony Biosciences, a healthcare company, focuses on developing treatments for r", "url": "https://www.sharewise.com/de/news_articles/A_beatendown_biotech_just_lost_a_meaningful_backer_should_you_care_TheMotleyFool_20260519_2353", "source_name": "www.sharewise.com", "published_at": "2026-05-20T02:09:07", "published_display": "20 May 2026 02:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director receives 21,872-share stock option grant", "summary": "Harmony Biosciences director Linda M. Szyper was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. This grant serves as compensation, not an open-market purchase, and vests fully on the earlier of May 14, 2027, or the next annual m", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-6195f3dfc2a1.html", "source_name": "Stock Titan", "published_at": "2026-05-19T07:10:44", "published_display": "19 May 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3", "summary": "Harmony Biosciences Holdings, Inc. director Germano Geno J has filed an initial Form 3 with the SEC, which officially lists him as a reporting person for the company. This filing is a mandatory first insider ownership report for company officers, directors, and large shareholders", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-3-harmony-biosciences-holdings-inc-initial-statement-of-benefici-4dfd4b9adbc3.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:39:21", "published_display": "19 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences (HRMY) director granted 21,231 stock options", "summary": "Harmony Biosciences Holdings, Inc. director Germano Geno J was granted 21,231 stock options as equity compensation. These options, with an exercise price of $30.76 per share and an expiration date of May 14, 2036, will vest in 36 equal monthly installments starting on June 14, 20", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-8306724de5f0.html", "source_name": "Stock Titan", "published_at": "2026-05-19T01:39:21", "published_display": "19 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences director granted 21,872 options | HRMY Insider Trading", "summary": "Harmony Biosciences director Philip Ron M was granted 21,872 stock options with an exercise price of $30.76 per share, expiring on May 14, 2036. The options will vest in full by May 14, 2027, or the date of the next annual meeting, contingent on his continued service. This transa", "url": "https://www.stocktitan.net/sec-filings/HRMY/form-4-harmony-biosciences-holdings-inc-insider-trading-activity-6d7dbcc5b2f9.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:39:21", "published_display": "18 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)", "summary": "Harmony Biosciences (HRMY) reported a dip in net income for Q1 2026, though net product revenue grew by 17%. The company is focused on WAKIX, having received FDA approval for pediatric cataplexy and actively pursuing patent protection into 2030, despite near-term earnings pressur", "url": "https://www.sahmcapital.com/news/content/earnings-dip-revenue-growth-and-patent-moves-might-change-the-case-for-investing-in-harmony-biosciences-hrmy-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-16T06:09:43", "published_display": "16 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Harmony Biosciences Holdings, Inc. \u2013 NASDAQ:HRMY", "summary": "This article provides limited information regarding the number of shareholders of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), indicating that data for specific periods and values can be accessed. It also notes various market data and reference data providers while listing ", "url": "https://www.tradingview.com/symbols/NASDAQ-HRMY/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-15T20:10:10", "published_display": "15 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Shareholders Approve Governance Measures at Meeting", "summary": "Harmony Biosciences Holdings (HRMY) shareholders recently approved key governance measures at their 2026 Annual Meeting. They elected four Class III directors, ratified Deloitte & Touche LLP as the independent auditor, and endorsed executive compensation, indicating strong shareh", "url": "https://www.tipranks.com/news/company-announcements/harmony-biosciences-shareholders-approve-governance-measures-at-meeting", "source_name": "TipRanks", "published_at": "2026-05-14T23:40:02", "published_display": "14 May 2026 23:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNDF4OHlBWkxnODQ3TTF5eGZqNVBUSGFQalF4NjBtR25TSmJfYzhjN0NhbERMSWRkak9yTmp5eXVSZU5RSnEzSjdYMzZWTEF4d0NQYjVoM2Ftcm5aUXU2MEVBRGNqQU1hZl9pZ01RbG5FMmZPQkZLXy1LZjNkV1RhSjBneGlmTmhFWmYzNHBUU1BuTUNXUzdmbC14V0dtSUhQOFB0bW9qZHpQdw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Harmony Biosciences\u2019 Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPUUgxMzFqMFRlN2JDZ3RObTRJSmhld2xZRUhaNFpqN0tRd1VxeEpJMkVXMWxSaGNpd1M1ZF9qbDZQMGhlQUZpblBoenU3VXI1djZ0VVczNTZIZlFWVUFqMVMtMk81UDl2Ri1DT0JSM3JBZjh6X3VfemN2WjdrdjJyR3RLR2tqUnByS0V5LUZLZDZIVm1XSzNOaHlXLXBVd2w1Z0c5b253?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN2tHV0E0dk1wWUxpUHNLZU1uME9DeG9uYVQwQTQtaXZwTzUtWWlyRTFOZDFCcGsyM1VQR2ZYb1YtUXNqUDM3OWVzUkRsSkxDdnJYa3ZfX2tjczdyajd6M2VtYnR0M2VDS25EQldLZ1h6TnJkVDEySnBOSlBwVGN4Vm5RalZnclY2c05ySU4yTlBZYW5aSk9mYUM2OWQ1Z2t3RWhrTE1BYmh3VnM5LUE?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit Harmony Biosciences Holdings (HRMY) After Its Recent Share Price Rebound?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond (NASDAQ:HRMY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQc05OcnBGRDJCdVpLUnJCM1J1XzRJUnktanZpamd2OVA5S3UxdjZ3VUZWeU5LS215UEtVSkRiODZ1blcwOUdmOHRXNTJsQms3WUxlUGdwTjJTSkRONjJsSHVpZjZMS0tlWTBlRTFQRlplZjJmRmhHMTFZNno1blFsQUlyV3RMeWtaR3Y4TE1TU21sYkN0MW4yT0xSaFZ3ZzNWNm5nRmVLeFk?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HARMONY BIOSCIENCES ($HRMY) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOMktvLU1lQ01BQVExVnlCQmVZQjBYUGp0dG1wbWVzRDd1TmNzSFA2UkZ0UzVZQ2hNM01LUm1mU3NBMEVIRG5yLU9HdnVjZldLRVpISkIwWlZYdEFPblVHY3NKWGR2d2tFRFUxYnNOZTVVNm5DQVE2ZVlGTVk3LTFpTXVwMzhxZmtkYkxQaUZ6cVZMcDdHdkZF?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Gains Pediatric WAKIX Approval As Valuation Draws Attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxPRVpWZVFMeVVrZ3VVN2MtOVlqWm8yb2tMeGZra2F3aU1WWmRSQzZtYUExVzBNRFZXZ1l1NUkzODA5NDNUSlh4bWtKY2RpbG04M2U5VUpCWUhrdjVuckVEbzFNcnEzaXJaamE3LTlHeTFsWHJVOG9FQ2RfMmVqZkFQV25YT3ZScy10ejVKYWhSTVRYcjB3RzNkN0s2TW8xQXVjOG9JOXc1QWZqS1JsU05vYVVpd2JnWDEzakFpc0xYMzN4UE1RcTg3WGNlSkQtdC0yYlp0cVA5RkU2WnpMdzJFTGctSjdqMGN3amkyLWd0TWtSY2d00gH6AUFVX3lxTE5aVFJ0NDhhbmFwS1g5ZUdlUWlVcEZsamYyeFdOOWRhY2NDaFJVZ0VNQTJRN1J0aXhUbkFIWEQ0T1ZkUWJXSXVZZy01Y1BpSVotSmdheGxBQkZmTVUza1RvYUJ0ek03c1FDenhwakhGaDFoaTVubkd4ZWhMMkFhbmk0MUExMGIwX21xaHQxbDJWa1lfTDRydm1mZi05bG1QbmFCX0JwSU1aMFVxcUhWdDcwUFVBX3RXNDF5RE5hS0dyWW8zUDNnWV9maXdpbUpqdUVHdEpBZTB2dkNZZFZlWmw1ZTNBR2EwS296dHhlOUQ3ZTNsby1STk12LXc?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOckpxNDNLWnpGZXpMYkFMNTZHUVdNQy1wMnJQd0p4bE5rZU1WM1d3UUpfWC03VGNJQ2dHOTNoX1p6Uk02cHMzN01mTUlfNVBtejdKRDQ0SlVRYjNodFgta2tsNS1yYmlQcWpKVm1TSXBPZ2RSMGVYUzJfb1N6THJsaTl1REwzSW85LUVoMjFiTGE1RUZGUnlhcDM0dGROTWpyUXEwZ3hmdHQyZUxjWE1IWmtaWGFmc2NDV2hnVFJWVVVJNjd5V0F1YXcwd1NRTExZZ1lNQkRPaHZFem1wTk0tWUF4NGlxbVE3RGdJZXo3dGxEM3NmOXpXWjhDNllOdTE1SGZlM0R6clBEaUxfa3RYMEdpcW5RWU9XYmZJanNVaWJhSHRLSXBVVUJvek4?oc=5", "source_name": "Business Wire", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPOEtsNnpwbnRDdGs4c0JmTzFOLXByTmtDMkJtNjl5NlMwLVhzTklDTnNYeDhrc1U5QUxIcTlZV3pvMmpTLU5QMzFoLWRXb1B4YjBtUFJQQ05ZX2pCdElyVkg5cW1HOGtCTVVPM3NnMWFoandjQzZwZjFEc29kR2UtNmUxbDFJd0NKWS1iYnRXaWozQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQaTZ3WlQ5VGtqVHJHOFgzYU93NG1aMV83WFRCakF4UUp0ZnktS1FGNHh3MUdleTBYcGxuem85dUhrSlc0U1NBTmM1Z0hDRlcya09XQ0c4Umd4OE5SbGpyZDZ6VXYxTkYyeHdhMU5HbGpvZ0FXMEhUa2ZjclJUOC14UXJCMTJmaDFVZjFB?oc=5", "source_name": "Market source", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVDJFeE1DS2JwR1l5b19ES3Z2SUlOVnk4cGV1VHhKR05qek04YTJUVHdad0VwemI0Z19FZno4Tl92Rk9yT1RaWmxNWElPV0JGSWJDU0N0dE9rY0RYbmFrTzd6dEd4SHhqWmtsSXRuQWNlNmpSdzRzZldhZzhMNHZPakhlbjRCZDRSbkhWSUQ2NTROR2I1YlFn?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Harmony Biosciences (HRMY) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNNjlfZWRuc2p0dmdJZzlsMU1GampfcE5jcUV2QTlDZ2FuYWZvNWNHb3hTcnFsOWlOWFNUMWZzNlQyempVVGh1MjVUZzJRZkwtX2xUVWgtWjVjOUtHNWlMa3QwWjRSby1QRTNTUzFIdHpMbFk4SzRuZHZ5R0dXUkxDRklZUG9CWjZmcHVnSEh3?oc=5", "source_name": "Market source", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Harmony Biosciences (HRMY) Pricing Reflect Future Growth After Recent Mixed Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPVFEyY3VKMmFOSmFGZHZpR0FrUDlUQnh1emJZbDZFeHJmbG1RSlJjcFE1VzFBa0RNVzZYWGRuQ29ZNDN5bE1WeUtlb3F2TGl1WmRvSTBIUzRrTVB5c0J5VmFWREF3S29nbWc0WE51cHVIYlAwc0w2TjRyaTNsMC02ZU1aQ3JQRXh5b0pUNnJVbw?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 55, "sentiment_summary": {"positive": 19, "negative": 3, "neutral": 33, "score": 55, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 8.94, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 33.28, "latest_week": "2026-06-19", "one_week_move": -3.4, "four_week_move": 10.4, "twelve_week_move": 25.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.724778, "market_dynamics_buy_signal": false, "relative_strength": -16.414646, "fair_value_gap": 1.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.8162, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.4% over one week, +10.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "simplywall.st", "count": 10}, {"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "AD HOC NEWS", "count": 1}, {"label": "Insider Monkey", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.4% over one week, +10.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Harmony Biosciences Stock - Analyst consensus and technical backdrop"}], "updated_at": "2026-06-22T18:01:58.468658+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}